8-K: Personalis Secures $36 Million Investment from Tempus AI, Expands Commercial Collaboration

Personalis, Inc. has secured a $36 million investment from Tempus AI through a share purchase and warrant exercise, while also expanding their commercial partnership.

Summary

• Personalis, Inc. entered into an investment agreement with Tempus AI, Inc. on August 16, 2024.
• Tempus purchased 3,500,000 shares of Personalis common stock at $5.07 per share, totaling $17,745,000.
• Tempus also exercised warrants to purchase 9,218,800 shares of Personalis common stock for $18,437,600.
• The total investment from Tempus is approximately $36 million.
• Personalis will use the proceeds for general corporate purposes and capital expenditures.
• The companies also amended their commercialization agreement, extending the termination notice period to 30 months and increasing Personalis's laboratory capacity commitments.
• Tempus will own approximately 19.3% of Personalis's outstanding common stock after the transactions.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the significant investment, expanded collaboration, and positive management comments. The deal is expected to be beneficial for both companies.

Positives

• Personalis secured a significant $36 million investment from Tempus.
• The expanded commercial collaboration with Tempus is expected to accelerate commercialization efforts.
• The extended termination notice period in the commercialization agreement provides more stability.
• Increased laboratory capacity commitments will allow Personalis to serve more patients.
• The investment strengthens Personalis's financial position and supports its growth strategy.

Risks

• The document mentions risks related to Personalis's ability to achieve milestones set forth in the collaboration agreement with Tempus.
• There are risks associated with processing the increased quantity of patient samples.
• The success of Tempus's sales and marketing efforts is crucial for the collaboration's success.
• The document references general risks and uncertainties detailed in Personalis's SEC filings, which could impact future results.

Future Outlook

The expanded collaboration is expected to accelerate commercialization efforts for Personalis's MRD testing products, with Tempus serving as the exclusive commercial partner. Personalis will increase its laboratory capacity to meet the anticipated demand.

Management Comments

• Chris Hall, CEO of Personalis, stated that the early access program is proceeding well and demand is strong.
• He also believes the expansion of the relationship with Tempus will allow Personalis to better capitalize on the opportunity.

Industry Context

This announcement highlights the growing interest and investment in personalized medicine and minimal residual disease (MRD) testing, particularly in oncology. The collaboration between Personalis and Tempus leverages Tempus's commercial reach and Personalis's technology to bring advanced MRD testing to market.

Comparison to Industry Standards

• The investment by Tempus is a significant endorsement of Personalis's technology and market position in the MRD testing space.
• The collaboration is similar to other partnerships in the biotech industry where companies combine their strengths to accelerate product development and commercialization.
• The 19.3% ownership stake by Tempus is a substantial investment, indicating a strong commitment to the partnership's success.
• The extended termination notice period in the commercialization agreement is a positive sign of long-term commitment between the two companies.

Related Party Transactions

• The investment agreement and the amendment to the commercialization agreement are related-party transactions between Personalis and Tempus.

Stakeholder Impact

• Shareholders will likely view the investment and expanded collaboration positively.
• Employees may benefit from the company's growth and increased resources.
• Customers (patients and healthcare providers) will have access to advanced MRD testing.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as more financially stable due to the investment.

Next Steps

• Personalis will file a registration statement with the SEC within 30 days to register the resale of the shares by Tempus.
• Personalis will increase its laboratory capacity to accommodate the increased patient samples.
• Tempus will accelerate its commercialization efforts for Personalis's MRD testing products.

Key Dates

Keywords

investment, Tempus AI, Personalis, warrants, share purchase, commercialization, laboratory capacity, MRD testing, cancer, genomic profiling